Core Insights - Novo Nordisk's recent trial data for its obesity drug CagriSema has underperformed compared to Eli Lilly's Zepbound, raising concerns about Novo's competitiveness in the weight-loss drug market [1] - Following the trial results, Novo's shares dropped by 16%, while Lilly's shares increased by 5%, indicating a shift in market sentiment towards Lilly's products [1] - Analysts express skepticism about Novo's ability to regain market share, citing repeated disappointments with CagriSema and the strong positioning of Lilly's portfolio [1] Novo Nordisk's Performance - CagriSema achieved a 23% reduction in body weight over 84 weeks, compared to a 25.5% reduction for Lilly's tirzepatide [1] - The trial results align with previous data for CagriSema but are seen as inferior to Lilly's offerings, which could solidify Lilly's dominance in the obesity market [1] - Novo's management attempted to downplay the trial results, but analysts and investors remain unconvinced, questioning the drug's value proposition [1] Market Dynamics - The obesity drug market is increasingly favoring Lilly, which has a stronger product range and is expected to receive U.S. approval for its weight-loss pill in April [1] - Novo's historical lead in the obesity drug market, particularly with the launch of Wegovy in 2021, has diminished as Lilly's valuation has surged to a trillion dollars [1] - Analysts suggest that Novo may struggle to compete effectively against Lilly's Zepbound, which is already well-established in the market [1]

The company said the weight-loss drug will be available at the same self-pay price in either the single-dose vial format or the multi-dose pen that delivers four weekly injections from a single device... ...

Eli Lilly Gains as Novo Nordisk Trial SetbackNovo Nordisk’s stock hit a 52-week low after its REDEFINE 4 trial failed to demonstrate non-inferiority in weight loss compared to Eli Lilly’s tirzepatide, marketed under the Zepbound and Mounjaro brands.The trial showed a weight loss of 20.2% with CagriSema versus 23.6% with tirzepatide, leading to a significant drop in Novo Nordisk shares.The REDEFINE 4 trial involved 809 subjects over 84 weeks, and while CagriSema demonstrated a safe profile, the results did n ...

Investors with a lot of money to spend have taken a bullish stance on Eli Lilly (NYSE:LLY).And retail traders should know.We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with LLY, it often means somebody knows something is about to happen.So how do we know what these investors just did? Today, Benzinga's options scanner spotted 26 ...

provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea.- Your healthcare provider should show you how to use Zepbound before you use it for the first time.Review these questions with your healthcare provider: Do you have other medical conditions, including problems with your pancreas, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting ...

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York on March 28, 2024.Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a single pen.Cash-paying patients can get the multi-dose device, called KwikPen, on the company's direct-to-consumer website, LillyDirect. Prices start at $299 per month for the lowest dose level. The pen could serve as a more convenient option for some patients, as it reduces the nu ...

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Ryan Maynard will join the company as Chief Financial Officer (CFO) on February 23, 2026. Mr. Maynard joins Foghorn with over 25 years of executive experience driving financial strategy, capital markets execution, and operational performance across publ ...

Novo shares slump after the Danish drugmaker's experimental obesity drug fails to beat Lilly's treatment in an 84-week trial. ...

Nvidia shares tick up as investors await the chip maker's fourth-quarter earnings, which likely will reveal how artificial-intelligence demand is holding up. ...

Core Viewpoint - Novo Nordisk shares faced pressure due to a head-to-head study indicating that its drug in development was less effective in weight loss compared to a product from Eli Lilly [1] Company Summary - Novo Nordisk is a Danish pharmaceutical company currently experiencing challenges with its drug development [1] - The company's recent study results have raised concerns about its competitive position in the market against Eli Lilly [1] Industry Summary - The pharmaceutical industry is witnessing intense competition, particularly in the weight loss drug segment, where efficacy is a critical factor for market success [1] - Eli Lilly's product has set a benchmark that other companies, including Novo Nordisk, must meet or exceed to remain competitive [1]